4-amino derivatives of the Hsp90 inhibitor CCT018159

被引：71

作者：

Barril, X

Beswick, MC

Collier, A

Drysdale, MJ

Dymock, BW

Fink, A

Grant, K

Howes, R

Jordan, AM

Massey, A

Surgenor, A

Wayne, J

Workman, P

Wright, L

机构：

[1] Vernalis Ltd, Cambridge CB1 6GB, England

[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 09期

关键词：

Hsp90; cancer; structure-based drug design; pyrazole; X-ray crystallography;

D O I：

10.1016/j.bmcl.2006.01.099

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Novel piperazinyl, morpholino and piperidyl derivatives of the pyrazole-based Hsp90 inhibitor CCT018159 are described. Structure-activity relationships have been elucidated by X-ray co-crystal analysis of the new Compounds bound to the N-terminal domain of human Hsp90. Key features of the binding mode are essentially identical to the recently reported potent analogue VER-49009. The most potent of the new compounds has a methylsulfonylbenzyl substituent appended to the piperazine nitrogen, possesses an IC50 of less than 600 nM binding against the enzyme and demonstrates low micromolar inhibition of tumour cell proliferation. (C) 2006 Elsevier Ltd. All rights reserved.

引用

页码：2543 / 2548

页数：6

共 18 条

[1]

BANJERI U, 2003, CURRENT CANC DRUG TA, V3, P385

[2] The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors [J].